Adaptimmune Therapeutics
Adaptimmune Therapeutics
ADAP
NASDAQ
1.27
USD
118.97%
About
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells.
Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS).
Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.4M |
| Three Month Average Volume | 41.3M |
| High Low | |
| Fifty-Two Week High | 2.05 USD |
| Fifty-Two Week Low | 0.42 USD |
| Fifty-Two Week High Date | 08 Mar 2024 |
| Fifty-Two Week Low Date | 21 Nov 2023 |
| Price and Volume | |
| Current Price | 1.27 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.75% |
| Thirteen Week Relative Price Change | 5.01% |
| Twenty-Six Week Relative Price Change | -27.36% |
| Fifty-Two Week Relative Price Change | 29.90% |
| Year-to-Date Relative Price Change | 35.24% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 12.39% |
| Twenty-Six Week Price Change | -20.13% |
| Five Day Price Change | 4.96% |
| Fifty-Two Week Price Change | 62.78% |
| Year-to-Date Price Change | 60.15% |
| Month-to-Date Price Change | -4.51% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.17394 USD |
| Book Value Per Share (Most Recent Quarter) | 0.37651 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.17248 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.37261 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.24512 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.2998 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.59222 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.56634 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.34518 USD |
| Normalized (Last Fiscal Year) | -0.60834 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.56634 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.34074 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.56634 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.34518 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.64683 USD |
| Cash Per Share (Most Recent Quarter) | 0.83999 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.51738 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.25607 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.19515 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -494 |
| Cash Flow Revenue (Trailing Twelve Months) | -33 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -50.49% |
| Pretax Margin (Last Fiscal Year) | -186.68% |
| Pretax Margin (5 Year) | -709.16% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -195.24% |
| Operating Margin (Trailing Twelve Months) | -54.54% |
| Operating Margin (5 Year) | -726.83% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -188.90% |
| Net Profit Margin (Trailing Twelve Months) | -51.25% |
| Net Profit Margin (5 Year) | -714.26% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -40.64% |
| Tangible Book Value (5 Year) | -30.71% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2,399.63% |
| Revenue Growth (3 Year) | 0.26% |
| Revenue Change (Trailing Twelve Months) | 99.90% |
| Revenue Per Share Growth | -13.27% |
| Revenue Growth (5 Year) | 147.88% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 0.72% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 331.04% |
| EPS Change (Trailing Twelve Months) | 36.21% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -189,835,000 |
| Net Debt (Last Fiscal Year) | -146,938,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 7 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 26 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -145,760,000 |
| Free Cash Flow (Trailing Twelve Months) | -46,614,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 26 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -37.24% |
| Return on Assets (Trailing Twelve Months) | -21.81% |
| Return on Assets (5 Year) | -41.19% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -187.61% |
| Return on Equity (Trailing Twelve Months) | -65.04% |
| Return on Equity (5 Year) | -78.66% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -48.02% |
| Return on Investment (Trailing Twelve Months) | -28.63% |
| Return on Investment (5 Year) | -48.21% |